S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2023
DOI: 10.1111/ddg.14930 ↗Kurz gefasst
Leitlinie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2023. Verfasst von Jürgen C Becker und 19 weiteren Autor:innen. Beteiligte Einrichtung: Translational Skin Cancer Research (TSCR), Deutsches Konsortium für translationale Krebsforschung (DKTK), Partnerstandort Essen, Department of Dermat…. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Skin Neoplasms, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Merkel cell carcinoma (MCC, ICD‐O M8247/3) is a rare, malignant, primary skin tumor with epithelial and neuroendocrine differentiation. The tumor cells share many morphologic, immunohistochemical, and ultrastructural features with cutaneous Merkel cells. Nevertheless, the cell of origin of MCC is unclear. MCC appears clinically as a reddish to purple spherical tumor with a smooth, shiny surface and a soft to turgid, elastic consistency, usually showing rapid growth. Spontaneous and often complete regressions of the tumor are observed. These likely immunologically‐mediated regressions explain the cases in which only lymph node or distant metastases are found at the time of initial diagnosis and why the tumor responds very well to immunomodulatory therapies even at advanced stages. Due to its aggressiveness, the usually given indication for sentinel lymph node biopsy, the indication of adjuvant therapies to be evaluated, as well as the complexity of the necessary diagnostics, clinical management should already be determined by an interdisciplinary tumor board at the time of initial diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Translational Skin Cancer Research (TSCR), Deutsches Konsortium für translationale Krebsforschung (DKTK), Partnerstandort Essen, Department of Dermatology, University Hospital Essen, German Cancer Research Center (DKFZ)…
- Department of Nuclear Medicine, University Hospital Ulm.
- Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Klinikum, Minden.
- Department of Dermatology, Venereology and Allergology, University Hospital Berlin.
- Department and Clinic for Dermatology and Allergology, LMU Klinikum Munich.
- Department of Dermatology, Venereology and Allergology, Ruhr University Bochum.
Zitieren
APA
Becker, J. C., Beer, A. J., DeTemple, V. K., Eigentler, T., Flaig, M., Gambichler, T., Grabbe, S., Höller, U., Klumpp, B., Lang, S., Pföhler, C., Posch, C., Prasad, V., Schlattmann, P., Schneider-Burrus, S., Ter-Nedden, J., Terheyden, P., Thoms, K., Vordermark, D., & Ugurel, S. (2023). S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.14930
Vancouver
Becker JC, Beer AJ, DeTemple VK, Eigentler T, Flaig M, Gambichler T, et al. S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2023. doi:10.1111/ddg.14930
BibTeX
@article{Becker2023,
author = {Becker, Jürgen C and Beer, Ambros J and DeTemple, Viola K and Eigentler, Thomas and Flaig, Michael and Gambichler, Thilo and Grabbe, Stephan and Höller, Ulrike and Klumpp, Bernhard and Lang, Stephan and Pföhler, Claudia and Posch, Christian and Prasad, Vikas and Schlattmann, Peter and Schneider-Burrus, Sylke and Ter-Nedden, Jan and Terheyden, Patrick and Thoms, Kai and Vordermark, Dirk and Ugurel, Selma},
title = {S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2023},
doi = {10.1111/ddg.14930}
}
EUVIMED